Evaluation of FDY-5301 in Major Trauma Patients in ICU

Stopped early · Phase 2 · Has a placebo group

Conditions studied: ICU Acquired Weakness

In brief

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)

Key facts

Study ID

NCT04430283

Run by

Faraday Pharmaceuticals, Inc.

People needed

8

Starts

2021-09-20

Expected to finish

2022-03-04

Last updated by the study team

2023-06-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years
• Major trauma defined as:
• thoracic and/or abdominal and/or pelvic injury
• necessitating admission to ICU with ventilation anticipated for at least 24 hrs
• hemorrhagic shock defined as systolic blood pressure (SBP) <90 mmHG requiring blood transfusion or base deficit of at least 6mEq/L pre-hospital arrival or within one hour after hospital arrival
• IRB/IEC-approved consent obtained within 48 hours of first hospital arrival time (i.e., in case of transfers, use time of arrival to first hospital immediately post injury)

You may not qualify if…

• Likely to die within 48 hrs from time of screening
• Any neurological condition that is perceived at the time of hospital admission as an immediate threat to life or incompatible with good functional recovery and where early limitation or withdrawal of therapy is being considered. For example:
• a. Computed tomography imaging showing evidence of traumatic brain injury (TBI), combined with best representative Glasgow Coma Score (GCS) Motor Score of ≤4 at approximately 24 hrs post injury
• Evidence of nonreversible spinal cord injury
• Bilateral femoral fractures
• Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative serum pregnancy test prior to randomization.
• Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization
• Known allergy to iodine
• Chronic renal disease requiring dialysis
• Body mass index (BMI) >40 kg/m2 or <16 kg/m2
• Body weight (BW) >140 kg (or >309 lb)
• History or presence of debilitating neurologic or other neuromuscular disease (e.g., spina bifida, amyotrophic lateral sclerosis, multiple sclerosis) at time of randomization
• Current metastatic cancer
• Solid organ transplant recipient
• Evidence of pre-existing sarcopenia defined as having a pre-trauma Clinical Frailty Score (CFS) of ≥5 or based on clinical judgement (e.g. frail by appearance, cachexia, etc.)
• Use of systemic corticosteroids, immunomodulators, or oncologic chemotherapy within 6 months of randomization (inhaled and topical steroids are allowed)
• Use of investigational drugs or devices within 30 days of randomization
• Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301

Where it is running

• Harbor-UCLA Medical Center — Torrance, California, United States
• University of Florida Health Shands Hospital — Gainesville, Florida, United States
• Massachusetts General Hospital, Harvard Medical School — Boston, Massachusetts, United States
• The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• Harborview — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.